Identification of double-stranded DNA in the cerebrospinal fluid of patients with acute neuromyelitis optica spectrum disorder. (January 2023)

• Record Type: Journal Article
• Authors: Yamamoto, Mamoru; Okuno, Tatsusada; Piao, Jin-Lan; Shimizu, Mikito; Miyamoto, Katsuichi; Nukui, Takamasa; Kinoshita, Makoto; Koda, Toru; Dini Haryuni, Ratna; Mochizuki, Hideki; Sugimoto, Tomoyuki; Nakatsuji, Yuji
• Is Part Of: Journal of clinical neuroscience. Volume 107(2023)
• Page Start: 129
• Page End: 132
• Publication Date: 2023-01
• Subjects: NMOSD -- dsDNA -- CSF; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2022.12.005
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: CSF dsDNA levels were elevated in patients with NMOSD. CSF dsDNA levels tended to decrease with treatment. CSF dsDNA levels showed a weak correlation with other CSF variables and length of spinal cord involvement. CSF dsDNA levels might reflect tissue destruction in patients with NMOSD. Abstract: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disease of the central nervous system (CNS) characterized by severe myelitis and optic neuritis. Double-stranded DNA (dsDNA) is involved in the pathogenesis of various autoimmune diseases, such as systemic lupus erythematosus. However, its role in NMOSD remains unclear. In this study, the concentration of dsDNA in the cerebrospinal fluid (CSF) was quantified in 23 patients with NMOSD and 16 patients with other neurological diseases (ONDs). CSF dsDNA levels in patients with NMOSD (median: 0.03 ng/µL) were significantly higher than those in patients with ONDs (median: 0.01 ng/μl). CSF dsDNA levels showed no significant difference before and after treatment. Elevation of CSF dsDNA levels may suggest its essential role in the augmentation of CNS inflammation in patients with NMOSD.